Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Pan Afr Med J ; 47: 167, 2024.
Artículo en Francés | MEDLINE | ID: mdl-39036032

RESUMEN

Intravenous thrombolysis is the standard treatment for acute ischemic stroke. We here report the cases of thrombolysis alert in the private sector in Morocco We conducted a prospective study of all patients with neurological deficit of sudden onset occurred within the first 12 hours admitted to the Emergency Department of the Al Badie international private clinic from January 2022 to September 2023. Epidemiological, clinical and etiological characteristics as well as data on outpatient and inpatient delays were collected. Sixty patients were included in the study. The average admission delay was 198.36 ± 79.23 minutes. The mean NIHSS (National Institutes of Health Stroke Scale) score was 10.41 ± 4.97. The average time for imaging was 26.68 ± 9.63 minutes. Ischaemic stroke was the most common diagnosis (85%), followed by "stroke mimics" (11.6%). Thirteen patients underwent thrombolysis with tenecteplase. The mean time from admission to the initiation of thrombolysis was 107.15 ± 24.48 minutes. Follow-up imaging at 24 hours post thrombolysis revealed symptomatic haemorrhagic transformation in 3 patients. Six patients were transferred to the Hassan II University Hospital for thrombolysis and/or mechanical thrombectomy. After 3 months, 4 patients were autonomous (Rankin score changed between 0 and 2). Our experience shows that it is imperative to reduce outpatient and inpatient delays in treatment in order to increase the proportion of patients treated with thrombolysis.


Asunto(s)
Fibrinolíticos , Accidente Cerebrovascular Isquémico , Terapia Trombolítica , Tiempo de Tratamiento , Humanos , Marruecos , Femenino , Persona de Mediana Edad , Accidente Cerebrovascular Isquémico/tratamiento farmacológico , Masculino , Terapia Trombolítica/métodos , Terapia Trombolítica/efectos adversos , Estudios Prospectivos , Anciano , Fibrinolíticos/administración & dosificación , Fibrinolíticos/efectos adversos , Estudios Transversales , Adulto , Tenecteplasa/administración & dosificación , Tenecteplasa/efectos adversos , Servicio de Urgencia en Hospital/estadística & datos numéricos , Factores de Tiempo , Trombectomía/métodos , Estudios de Seguimiento , Activador de Tejido Plasminógeno/administración & dosificación , Activador de Tejido Plasminógeno/efectos adversos , Anciano de 80 o más Años
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...